Marketing a semaglutide or tirzepatide program without losing the ad account.
Most clinics running a GLP-1 program lose months to advertising problems that have nothing to do with their offer. The medication is named in the ad, the account gets restricted, and the whole program stalls. ScaleClinics builds the acquisition system around what the platforms actually permit, so the campaign keeps running and the medical detail lives where it belongs.
How to market a GLP-1 program that the platforms will actually run
The constraint in this vertical is not creative and it is not budget. It is that the thing you sell is a prescription medication, and every major ad platform treats that as a restricted category with automated enforcement. The system has to be built around that from the first day rather than patched after the first rejection.
Authorization and account setup first
Business portfolio verification, ad account, page, and dataset configured before anything runs, plus the certification and platform authorization path where your program requires it. This sequencing is what separates clinics that launch from clinics that keep getting rejected.
Advertising that does not name the prescription
The ad sells the outcome the patient wants and the program that delivers it. The medication is discussed after the click, where ad policy no longer governs the conversation.
A funnel that does the medical qualifying
Intake that screens for eligibility and sets expectations about cost, process, and what a clinician will need, so your team is reviewing candidates rather than tire-kickers.
Tracking wired to the checkout
Server-side conversion events from your provider platform, so campaigns optimize toward patients who paid rather than people who filled in a form.
How the system is specified
to first contact on a new inquiry, by AI phone call
of automated follow-up by text, email, and phone
conversion events, sent from the checkout rather than the browser
These are specifications of the system we build, not performance claims. Results depend on your offer, your market, your price point, and how fast your clinicians work.
The guarantee
We agree on a patient number for your program on the strategy call, sized to your ad budget. If we miss it within 90 days, we keep managing the account at no further management cost until we reach it. Ad spend is paid directly to Meta and never to us. The clock starts when your main patient ads go live, which in this vertical is often later than clinics expect because authorization is not something anyone can rush.
“Clinics lose more money in this vertical to a restricted ad account than to an expensive click. An account that stays live for six months beats a punchier ad that gets pulled in week two, every single time.”
Built for telehealth clinics running a medication-based weight loss program
ScaleClinics works with cash-pay telehealth clinics whose patients complete intake and pay online, nationwide. That includes clinics dispensing compounded formulations through a partner pharmacy and clinics prescribing branded products, because the advertising problem is similar even though the regulatory position is not.
We do not advertise investigational compounds that lack FDA approval. That is not a policy preference. Products in that category have drawn federal warning letters and enforcement actions against the clinics promoting them, and no acquisition system is worth that exposure. If your program is built on one, we will say so on the first call.
We also do not work with insurance-billing practices or research-use-only catalogues, and since August 2026 we work with telehealth only.
What you can and cannot name in a weight loss ad
There are three separate layers here and clinics routinely collide with all of them at once.
The first is the restricted-goods layer. Prescription medication is a restricted category on Meta, and promoting it requires a specific advertising permission. That permission has a certification prerequisite which takes real time and real money to obtain. Whether you hold it determines whether you may name a prescription product in an ad at all, and most clinics discover this only after building a campaign around language they were never eligible to use.
The second is the personal attributes layer, and this is the one that surprises people, because it is not about vocabulary at all. Copy that implies the advertiser knows something about the health or body of the person reading it is a violation even when every individual word is unremarkable. A question that asks the reader about their own weight is the classic example. The fix is not a gentler synonym. It is to stop addressing the reader's body and describe the program or the experience instead.
The third is brand names. Ads for compounded formulations are expected to strip references to branded products, which means the recognizable trade names most patients search for are the ones least available to you in an ad. There is no workaround worth running. Trading on another manufacturer's trademark to sell a compounded alternative is both a policy problem and a legal one.
The practical consequence is that the ad carries the outcome and the program, and the medication conversation happens after the click. Ad policy governs the ad. It does not govern your intake, where you can and should be specific about what is prescribed, how it is supervised, and what it costs.
Compounded and branded are two different advertising problems
Clinics talk about running a GLP-1 program as though it were one thing. From an advertising and regulatory standpoint it is two, and the distinction decides how much risk your marketing carries.
A clinic prescribing an FDA-approved branded product is working with a well-defined regulatory object. The advertising constraints are meaningful but stable, and the questions are mostly about platform permission.
A clinic dispensing a compounded formulation through a partner pharmacy sits somewhere more complicated. Compounded preparations are not approved products in the same sense, the rules around when compounding is permitted have moved repeatedly, and the enforcement climate has tightened sharply since state attorneys general pressed the platforms at the end of 2025. Everything downstream of that, including what your landing page may claim and how your guarantee is worded, changes with it.
We ask which one you are on the first call, because the answer changes the creative strategy, the authorization path, and in some cases whether we take the engagement at all.
Why the regulatory temperature went up, and what it means for your marketing
Two things happened in close succession. A large group of state attorneys general pressed Meta at the end of 2025 over weight loss drug advertising, and federal regulators began issuing warning letters to clinics and med spas over how these products were being promoted, with particular attention to social media.
The enforcement did not land evenly on the obvious offenders. It landed on specific messaging patterns: body-dissatisfaction framing, before-and-after transformation imagery, and deadline urgency built around weddings or holidays. Those three angles were the most reliable performers in weight loss advertising for a decade, which is precisely why they drew attention.
For a clinic this means the playbook circulating in operator groups is often several enforcement cycles out of date, and copying an ad you saw running is not evidence it is safe. Ads run until they are caught. We write against the current policy and the current enforcement posture, and we accept a quieter ad that survives over a sharper one that does not.
What to build instead of naming the drug in the ad
The good news is that the compliant version usually converts better, because it reaches people earlier.
Someone searching a medication by name has already decided what they want and is comparing prices. That is a small, expensive, late-stage audience. The far larger group knows how they feel and what they have already tried and has not settled on a treatment. An ad that describes that experience reaches them, and by the time they arrive at your intake they are open to a recommendation rather than shopping a specific prescription.
So the ad carries the outcome and the program. The funnel carries the medical specifics, the eligibility screening, and the price. Follow-up carries the rest, because a decision this consequential is rarely made in one sitting, and most of the patients you will actually treat come from the third or fourth contact rather than the first.
Marketing a GLP-1 medication program, answered
Can you advertise semaglutide or tirzepatide on Facebook and Instagram?
Not by naming the medication in the ad unless you hold the platform's prescription advertising permission, which itself requires a certification most clinics do not have when they start. What does run reliably is advertising the program and the outcome without naming the prescription, then handling the medical specifics after the click, where advertising policy no longer applies. Ads for compounded formulations are also expected to avoid branded product names entirely.
Why does my weight loss ad keep getting rejected when the copy looks harmless?
Usually the personal attributes rule rather than the restricted-goods rule. Copy that implies you know something about the reader's body or health is a violation even when no individual word is on any list, which is why asking the reader a direct question about their own weight tends to fail. The fix is to describe the program or the experience rather than addressing the reader's body. A secondary cause is account signals: a new ad account, an unverified business portfolio, and a page with no history all read as risk in combination.
Is marketing a compounded GLP-1 program different from marketing a branded one?
Yes, and the difference matters more than most clinics expect. A branded FDA-approved product is a stable regulatory object and the questions are mostly about platform permission. A compounded formulation dispensed through a partner pharmacy sits in a more contested position, the rules have moved repeatedly, and enforcement tightened considerably after state attorneys general pressed the platforms at the end of 2025. We ask which one you run on the first call because it changes the strategy and sometimes the answer.
Do you advertise investigational compounds that are not FDA approved?
No. Products in that category have drawn federal warning letters and enforcement actions against the clinics promoting them, not only platform penalties, and the exposure sits with whoever ran the ad rather than whoever supplied the product. If your program is built on one we will tell you on the first call rather than take the engagement.
What does a semaglutide marketing agency actually do?
It runs the pipeline that turns a stranger into a paying weight loss patient while keeping the ad account alive: platform authorization and account setup, advertising written against current policy, an intake funnel that screens for eligibility and handles the medical detail, fast follow-up on every inquiry, and conversion tracking that reports what was actually paid for. ScaleClinics builds and operates all of it rather than handing over a list of contacts.
How long does it take to launch a compliant GLP-1 campaign?
The build itself takes a few weeks. The variable is authorization, because certification and platform permission are processes nobody can rush and they are measured in weeks rather than days. Our 90-day guarantee period starts when the main patient ads go live rather than when you sign, precisely because that waiting period is outside anyone's control.
Stop chasing leads.
Start stacking patients.
15-minute strategy call. We'll look at how you're getting patients now, tell you what we'd change, and give you a guaranteed patient number for your clinic.
Book your strategy call